Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

An Off Broadway play opens a window on the spiritual and physical trials of the ancient Japanese sport.

Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...